A Phase 1 interventional study of Eradication of Helcobacter Pylori in Chronic Obstructive Pulmonary Disease (COPD) and With Poitive H Pylori, sponsored by Zagazig University. Recruiting at 1 site in Egypt. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Zagazig University · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Pulmonary Disease, Chronic Obstructive with a site in Egypt — 26 open to participants now, 28 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Egypt.
Among the 85 studies in Pulmonary Disease, Chronic Obstructive with a site in Egypt, this one is the 44th largest by planned enrollment of the 53 interventional ones that give a count, is one of 6 that started in 2026, is one of 3 in phase 1, reaches primary completion later than 18 of the 27 other live ones, and was the 75th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →26 of the 85 studies in Pulmonary Disease, Chronic Obstructive with a site in Egypt are open now. Recruiting first, the newest first:
Assiut University · Sites in Egypt
Ages 40+
Sohag University · Sites in Egypt
Ages 18+
AstraZeneca · Sites in Egypt, Argentina, Mexico and 4 more countries
Ages 18+
AstraZeneca · Sites in Egypt, Argentina, Colombia and 9 more countries
Ages 30–80
Mohammed Shehta · Sites in Egypt
Ages 40+
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 4 · Phase 4 3
First in 2006; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 54 is below the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 60 across the 53 interventional studies, 100 across the 32 observational. Of the 41 that completed or were terminated, 3 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 85 have an industry lead sponsor. The 10 most frequent:
Zagazig University is the lead sponsor of 462 studies on the registry; 78 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Zagazig University has 1 study filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
4 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07854210Mohammed ShehtaHFNC Versus NIV in Hypercapneic COPD Patients | 2026-11 |
| NCT07579052Assiut UniversityCLEAR Model for Predicting Ventilatory Liberation in Severe COPD | 2027-04-01 |
| NCT07245576AstraZenecaAssess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis | 2027-04-30 |
| NCT07590362Sohag UniversityD-RSBI Versus RSBI for Predicting Weaning Success in COPD Patients | 2027-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 85 studies in Pulmonary Disease, Chronic Obstructive with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Helicobacter pylori (HP) is a well-established pathogen responsible for chronic gastritis and peptic ulcer disease. Its presence has been implicated in the development of gastric malignancies such as adenocarcinoma and mucosa-associated lymphoid tissue lymphoma. Chronic H. pylori infection is associated with systemic inflammatory responses and various extra gastric diseases, including cardiovascular, metabolic, and neurological disorders. Furthermore, H. pylori infection contributes to gastrointestinal dysbiosis by interacting with gastrointestinal microbiota, which may be involved in gastric carcinogenesis and other systemic disorders. Growing evidence highlights the role of dysbiosis in chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and asthma. Emerging epidemiological evidence suggests a potential association between H. pylori infection and respiratory diseases, including COPD. Several observational studies and meta-analyses have found that H. pylori infection in patients with COPD may be associated with systemic inflammatory markers and altered pulmonary function parameters. Despite these associations, the causal mechanisms underlying this relationship remain unclear. Furthermore, it is uncertain whether eradication of H. pylori yields measurable benefits on clinical outcomes in COPD patients. So, Our aim to evaluate changes in symptoms, pulmonary function, and inflammatory markers after H. pylori eradication therapy in the H. pylori-positive COPD patients.
an intervention study (quasi experimental), study will be carried out in the inpatient and outpatient clinics of Chest Department, Faculty of Medicine, Zagazig University hospitals.
Patients included in the study:
well controlled COPD patients attending outpatient clinics for a period of 6 months fulfilling inclusion and exclusion criteria will be included in this study.
An interventional study (quasi experimental), this study will be carried out in the inpatient and outpatient clinics of Chest Department, Faculty of Medicine, Zagazig University hospitals.
-Patients included in the study: well controlled COPD patients attending outpatient clinics for a period of 6 months fulfilling inclusion and exclusion criteria will be included in this study.
All patients diagnosed with COPD attending the study setting during the specified study period (6 months) will be consecutively screened for Helicobacter pylori infection.
All eligible patients who test positive for H. pylori will be included in the intervention phase and will receive eradication therapy.
Therefore, a consecutive sampling technique will be applied, all available cases during the study period will be recruited. Based on the expected patient flow, approximately 108 COPD patients are anticipated over 6 months, with an estimated H. pylori prevalence of around 50% ((Abdelmagied etal., 2019), yielding about 54 cases for the intervention phase.
All patients will be subjected to the following:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For H. pylori-positive COPD patients: administer standard eradication therapy according to current guidelines (e.g., triple or quadruple therapy with proton pump inhibitor and antibiotics).
Drug: Eradication of Helcobacter Pylori
Pre- intervention stage:Perform baseline spirometry and laboratory markers, Assess severity of COPD according to GOLD criteria: stage 1 (FEV1 ≥80%), stage 2 (50% ≤FEV1 \<80%), stage 3 (30% ≤FEV1 \<50%), and stage 4 (FEV1 \<30%). * Intervention stage: For H. pylori-positive COPD patients: administer standard eradication therapy according to current guidelines (e.g., triple or quadruple therapy with proton pump inhibitor and antibiotics). Confirm eradication at least 4-6 weeks after therapy completion via repeat testing. * Post intervention: Reassess COPD symptoms, lung function, and biomarkers 3 months after successful H. pylori eradication. Follow up H. Pylori-positive COPD patients for 3months by reassessment of COPD symptoms, lung function and biomarkers.
Primary outcome measures
Reassess symptoms of COPD by COPD Assessment Test (CAT): The COPD Assessment Test (CAT) is a questionnaire for people with COPD. It is designed to measure the impact of COPD on a person's life, and how this change over time. The CAT is a standard and validated test containing eight items for the evaluation of the impact of COPD on health status
Time frame: 3 months
FEV₁ - Volume exhaled in first second
FEV₁ - Volume exhaled in first second; Unit: L
Time frame: 3 months after treatment
FVC - Total forced exhaled volume; Unit: L
FVC - Total forced exhaled volume; Unit: L
Time frame: 3 months after treatment
FEV₁/FVC Ratio - Airflow limitation index; Unit: %
FEV₁/FVC Ratio - Airflow limitation index; Unit: %
Time frame: 3 months after treatment
CRP - Systemic inflammation marker; Unit: mg/L
CRP - Systemic inflammation marker; Unit: mg/L
Time frame: 3 months after treatment
PaO₂ - Arterial oxygen pressure; Unit: mmHg
PaO₂ - Arterial oxygen pressure; Unit: mmHg
Time frame: 3 months after treatment
PaCO₂ - Arterial carbon dioxide pressure; Unit: mmHg
PaCO₂ - Arterial carbon dioxide pressure; Unit: mmHg
Time frame: 3 months after treatment
pH - Arterial acid base status
pH - Arterial acid base status
Time frame: 3 months after treatment
Plan to share: No — Due to privacy of data
Ran from Mar 2026 to primary completion in Sep 2026, 6 months.
Of 176 phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 6 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →